Gilead Sciences stock pill meets trial goal, slightly lower pre-market
Published on 10/20/2026 at 07:45 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWSUlcerative colitis trial reaches endpoint
- Gilead Sciences reported positive mid-stage ulcerative colitis trial results on October 19, 2026.
- Third-quarter financial results are scheduled for October 29, 2026.
- Gilead Sciences stock trades pre-market at EUR 136.70 at 7:44 a.m. CEST at Lang & Schwarz on October 20, 2026, 0.57 percent below the Xetra close of October 19, 2026.
Gilead Sciences said its experimental ulcerative colitis pill succeeded in a mid-stage trial on October 19, 2026, according to MarketScreener. Gilead Sciences stock trades pre-market at EUR 136.70 at 7:44 a.m. CEST at Lang & Schwarz on October 20, 2026, 0.57 percent below the Xetra close of October 19, 2026 (EUR 137.48).
Trial update for ulcerative colitis
The report identified the study as a Phase 2 trial of emvistegrast, an experimental once-daily oral treatment for ulcerative colitis. MarketScreener listed the item among Gilead Sciences press releases dated October 19, 2026.
Ahead of the Xetra open
The stock is EUR 0.78 below the Xetra close. The further course from the Xetra open at 9:00 a.m. CET/CEST is shown by the continuously updated real-time quote of Gilead Sciences stock.
The group and its market
Gilead Sciences develops medicines in virology, oncology and inflammation, according to its company website. Its third-quarter 2026 financial results are scheduled for October 29, 2026, according to MarketScreener. Market context: Market report Nasdaq Composite.
